Skip to main content
Clinical Trials/JPRN-UMIN000015184
JPRN-UMIN000015184
Completed
Phase 2

Phase II study of pre and post operative combination chemotherapy using carboplatin and dose dense paclitaxel (dose dense TC therapy) for locally advanced cervical cancer - SGSG016 study

Sankai Gynecology Study Group0 sites50 target enrollmentSeptember 18, 2014

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
FIGO stage Ib2, IIa2, or IIb cervical cancer
Sponsor
Sankai Gynecology Study Group
Enrollment
50
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 18, 2014
End Date
December 31, 2016
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Sankai Gynecology Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Prior chemotherapy nor radiation therapy for cervical cancer. 2\. Simultaneous active cancer. 3\. Serious coexisting illness 4\. Carrier of viral hepatitis 5\. Active infection 6\. Interstitial pneumonia

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer
KCT0002936Asan Medical Center20
Active, not recruiting
Phase 1
A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable oestrogen receptor positive primary breast cancerntreated, operable ER+, HER2-negative primary breast cancer.MedDRA version: 21.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-004424-38-DEQueen Mary University of London97
Active, not recruiting
Phase 1
A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable oestrogen receptor positive primary breast cancerntreated, operable ER+, HER2-negative primary breast cancer.MedDRA version: 21.1 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-004424-38-GBQueen Mary University of London57
Active, not recruiting
Phase 1
PANCEP-1Pancreatic cancerTherapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2023-506979-10-00Vaestra Goetalandsregionen50
Completed
Not Applicable
Clinical trial phase 2 evaluating postoperative visual functions in eyes with epiretinal membrane with good visual acuity better than 0.9 decimal unitepiretinal membrane
JPRN-UMIN000021116ihon University hospita40